Other languages Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Real-time Estimate Cboe BZX Other stock markets 15:02:42 2024-06-26 EDT			5-day change	1st Jan Change
0.448 ^USD	+3.56%		+6.21%	+44.95%

06-24	Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder	CI
05-15	Brookline Capital Upgrades Dare Bioscience to Buy From Hold, Price Target is $3	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Dare Bioscience, Inc. Announces Publication in Obstetrics & Gynecology of Phase 2B Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder	06-24
Daré Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14
Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC	04-30
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	04-29
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	04-23
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	01-31
Daré Bioscience, Inc. Announces Executive Changes	01-26
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned	01-26
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study	12-20
Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment	12-07
Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug Application for DARE-VVA1	12-07
Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive	12-04
Dare Bioscience Extends Agreement With Premier Research to Advance Reproductive Health Portfolio	11-20
Dar Bioscience, Inc. and Premier Research International LLC Extend Strategic Partnership to Accelerate the Clinical Development of Dar's Novel Women's Health Programs	11-20
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	11-09
Dare Bioscience Says Additional Data Show Sildenafil Cream Improving Sexual Disorder Symptoms	11-01
Sector Update: Health Care Stocks Rise Late Afternoon	23-10-16
Sector Update: Health Care Stocks Gaining Monday Afternoon	23-10-16
Dare Bioscience Triggers $1.8 Million Milestone Payment from Organon With Xaciato's First Shipment	23-10-16

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Other languages

Filters